GRRRRRR!
$Aptevo Therapeutics (APVO.US)$ Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Accesswire· 9 mins ago
SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-273067), on Form S-3 (File No. 333-275710), on Form S-1 (File No. 333-278103), on Form S-1 (File No. 333-280226) and on Form S-1 (File No. 333-281892). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $6.2 million, before deducting financial advisory fees.
Roth Capital Partners is acting as the Company's financial advisor for this transaction.
In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 1,647,088 shares of common stock, at an exercise price of $9.53 per share and will be immediately exercisable upon issuance and for a term of five years from the issuance date.
The offering is expected to close on or about December 13, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capitaland general corporate purposes.
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
Accesswire· 9 mins ago
SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-273067), on Form S-3 (File No. 333-275710), on Form S-1 (File No. 333-278103), on Form S-1 (File No. 333-280226) and on Form S-1 (File No. 333-281892). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $6.2 million, before deducting financial advisory fees.
Roth Capital Partners is acting as the Company's financial advisor for this transaction.
In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 1,647,088 shares of common stock, at an exercise price of $9.53 per share and will be immediately exercisable upon issuance and for a term of five years from the issuance date.
The offering is expected to close on or about December 13, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capitaland general corporate purposes.
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit OP : With LOCK UP on December 17th! I really wasn’t expecting this on top of that coming! Grrrr! Hehehe!
A yyds : A little confused, is this considered good news?
Trytosaveabit OP A yyds : Nooo! Well short term it’s not good! Long term sure it’s good for company
Trytosaveabit OP Aukina24 : That’s no lie! Im sure glad I always scale out some to secure profits! Otherwise this woulda really handed my ass to me! Hehehe! Because of scaling out I only got a quarter of a ass cheek handed to me! Hehehe
Aukina24 Trytosaveabit OP : Down over 51%. FML
Trytosaveabit OP Aukina24 : Ouch! Im sorry! One thing! There may be a lot of people that have been waiting on the sidelines for a lower price to get in? And if so. That could over the next few days cause a decent amount of buy side pressure as they use this massive drop to buy? Just speculation. But I am looking at it as a buy opportunity when it finds bottom!
A yyds Trytosaveabit OP : 我损失了40%![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
102539778 : wow just got rugpulled
Trytosaveabit OP 102539778 : Not just pulled! They rolled it up and ran away with it! Hehehe